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Molecular forms of the glucagon-like peptides (GLP) encoded by the human preproglucagon gene were ana- 
lysed by chromatography combined with specific radioimmunoassays to the synthetic peptides. Whereas 
extracts of human pancreas and a glucagonoma contained a large proglucagon cleavage product possessing 
both GLP-1 and GLP-2 immunoreactivities, extracts of human intestine contained products corresponding 
to free GLP-1 and a small amount of chromatographically distinct GLP-2 immunoreactivity. It is concluded 
that post-translational processing of proglucagon differs in pancreas and intestine, so that the C-terminal 
portion of the molecule is cleaved to liberate free GLP-1 in the intestine. Further processing or degradation 
results in loss especially of GLP-2 immunoreactivity. 
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1. INTRODUCTION 
The human preproglucagon gene encodes 2 fur- 
ther glucagon-like peptide sequences, GLP-1 and 
GLP-2, in the C-terminal portion of proglucagon 
[ 11. These sequences are well conserved between 
mammalian species [2], suggesting that they have a 
significant biological role, but their post- 
translational cleavage in human pancreas and in- 
testine has not been fully described. We have 
previously shown, by the use of an antiserum 
raised to a synthetic N-terminal fragment of 
GLP-1, that relatively little free GLP-1 is produced 
in the human pancreas [3]. Here, we have used an- 
tisera raised against synthetic entire sequences of 
GLP-1 and GLP-2 to investigate further their 
molecular forms in the human pancreas, a pan- 
creatic glucagon-secreting tumour, and the human 
intestine. 
2. MATERIALS AND METHODS 
2.1. Materials 
Synthetic GLP-1 was purchased from Bachem, 
* TO whom correspondence should be addressed 
CA, USA; synthetic des-Gly3’-GLP-1 amide and 
human GLP-2 from Peninsula Laboratories, CA, 
USA; and bovine serum albumin (BSA, Cohn frac- 
tion V) from Sigma. Other reagents were of 
analytical grade. 
2.2. Radioimmunoassays (RIA) 
GLP-1 and GLP-2 were conjugated to BSA in a 
molar ratio (peptide :protein) of 4: 1 by 
bisdiazobenzidine and glutaraldehyde methods [4], 
respectively. Four rabbits were immunised with 
each conjugate in Freund’s complete adjuvant, 
and boosted at monthly intervals. Serum collected 
after the second and subsequent boosts were used 
for RIA. GLP-1 and GLP-2 were trace-iodinated 
with Carrier-free Na’*‘I [5] and purified by reverse- 
phase, high-pressure liquid chromatography 
(HPLC) as described in [3], under isocratic elution 
with water : acetonitrile :trifluoroacetic acid (574 :
425 : 1, v/v). Specific activities of the GLP-1 and 
GLP-2 tracers, as estimated by self-displacement 
from the appropriate antibody, were 81 and 20 
Bq/fmol respectively, GLP-2 presumably being 
labelled on the sole His’ residue. RIA methods [3] 
and RIA for glucagon-like immunoreactivity 
(GLI) [6] were as described, using 0.2 M glycine 
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sodium buffer, pH 8.8, containing 0.05qo (w/v) 
sodium azide and 1% (w/v) BSA. The detection 
limit (95070 confidence) for GLP-1 was 1.25 
fmol/ml, and 5 fmol/ml for GLP-2. Cross-re- 
activities of glucagon and GLP-2 in the GLP-I 
assay were 0.3 and <O.Ol% respectively, of 
glucagon and GLP-1 in the GLP-2 assay < 0.01%) 
and of GLP-I and GLP-2 in the GLI assay 
<O.Ol%. There were no significant cross- 
reactivities with other pancreatic or intestinal 
regulatory peptides. 
2.3. Tissues and extraction 
Five specimens of histologically normal human 
pancreas, specimens of human intestine and a 
human pancreatic glucagonoma removed at 
surgery were immediately frozen in liquid nitrogen 
and stored at - 20°C before extraction for 15 min 
in 0.5 M acetic acid (10 ml/g wet wt tissue) at 
100°C. 
2.4. Chromatography 
Gel filtration was performed at 4’C on a column 
(80 x 1.4 cm diameter bed) of Sephadex G-50 
superfine eluted with assay buffer at a flow rate of 
5 ml/h. Elution positions were expressed in terms 
of K,, [7] and dextran blue (Mr 2 x 106, K,, 0), 
horse heart cytochrome c (MI 12384, K,, 0.17) and 
Na’? (K,, 1.0) were used as markers. HPLC was 
performed as described [3], with linear gradients of 
water : acetonitrile : trifluoroacetic acid (699 : 300 : 
l-399 : 600 : 1, v/v) over 60 min. The flow rate was 
1 ml/min and 2-ml fractions were collected. 
3. RESULTS 
Gel filtration of 5 human pancreas extracts gave 
variable profiles of GLP-1 and GLP-2 im- 
munoreactivities. However, a common feature was 
a peak of K,, 0.15 containing both GLP-1 and 
GLP-2 immunoreactivities, with a smaller peak of 
GLP-1 immunoreactivity at K,” 0.43, the elution 
position of synthetic GLP-1 (fig.lA). In the K,, 
0.15 peak, the ratio of GLP-1 to GLP-2 im- 
munoreactivities was approx. 1: 1 in 4 cases, but 
1:0.3 in one case. HPLC (fig.2A) also 
demonstrated a peak (fractions 19-22) containing 
both GLP-1 and GLP-2 immunoreactivities, and 
an earlier peak (fractions 16-18) of GLP-1 im- 
munoreactivity in the position of synthetic GLP-I 
GLP 
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Fig. 1. Sephadex G-50 chromatography of human tissue 
extracts analysed for GLP-I (0) and GLP-2 (A) 
immunoreactivities. (A) Pancreas, (B) glucagonoma, (C) 
ileum. Arrows show the elution positions of horse heart 
cytochrome c (CC) and synthetic GLP-1 and GLP-2 
markers, 
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Fig.2. HPLC profiles of human tissue extracts analysed 
for glucagon-like immunoreaactivity (hatched bars), 
GLP-1 immunoreactivity (open bars) and GLP-2 
immunoreactivity (solid bars). (A) Pancreas, (B) 
glucagonoma, (C) ileum. Arrows show the elution 
positions of pancreatic glucagon (PG) and synthetic 
GLP-1 and GLP-2 markers. 
or des-Gly3’-GLP-1 amide, which were not 
separated in this system. GLI emerged as a peak of 
pancreatic glucagon (fractions 12-13), preceded 
by material that may correspond to N-terminally 
extended forms of pancreatic glucagon [8]. 
The pancreatic glucagonoma extract also con- 
tained a peak at KaV 0.15 with a GLP-1 to GLP-2 
immunoreactivity ratio of 1: 0.25, a small peak of 
GLP-2 immunoreactivity at K,” 0.23, and a 
substantial peak of GLP-1 immunoreactivity at Kav 
0.43 (fig.lB). The corresponding HPLC profile 
showed a peak with GLP-1 and GLP-2 im- 
munoreactivities (fractions 19-22), with a peak 
corresponding to free GLP-1 at fractions 16-18 
(fig.2B). 
By contrast, gel filtration of human ileal extract 
gave only a single peak of GLP-1 immunoreactivi- 
ty at K,, 0.43, and fused peaks of GLP-2 im- 
munoreactivity at K,, 0.20-0.31 (fig.lC). HPLC 
confirmed the presence of GLP-1 immunoreactivi- 
ty emerging in the position of synthetic GLP-1, 
and showed a separate peak of GLP-2 im- 
munoreactivity in the position of synthetic GLP-2 
(fig.2C). However, the gel-filtration profile sug- 
gested that this must consist of at least 2 extended 
forms of GLP-2 that were not distinguishable from 
synthetic GLP-2 in this HPLC system. Similar pat- 
terns were obtained for human colon and rectum. 
Ratios of GLI : GLP-1: GLP-2 immunoreactivities 
recovered in the HPLC peaks were 100:42:22 for 
ileum, 100:47: 8 for colon and 100: 82:23 for 
rectum. 
4. DISCUSSION 
When these results are interpreted in the light of 
the deduced structure of human preproglucagon’ 
[l], it is apparent that the human pancreas con- 
sistently produces a proglucagon fragment that 
emerges before horse heart cytochrome c on gel 
filtration, contains both GLP-1 and GLP-2 im- 
munoreactivities, but is devoid of GLI. This is 
compatible with the production of a cleavage 
product consisting of GLP-1 linked to GLP-2 via 
the intervening ‘spacer’ peptide. Pulse-chase 
studies on proglucagon biosynthesis in rat islets 
have demonstrated this fragment to be the prin- 
cipal or sole product from the C-terminal portion 
of rat proglucagon [9]. The situation in the human 
pancreas is more complex, as there is also some 
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production of free GLP-1, and an occasional 
deficit of GLP-2 immunoreactivity in the Kav 0.15 
peak. This implies that there is some cleavage at 
the C-terminus of the GLP-1 sequence, and also 
some degradation or derivatisation within the se- 
quence of GLP-2, reducing the GLP-a-like im- 
munoreactivity in this peak. In the pancreatic 
glucagonoma there was also a deficit of 
GLP-Zlike immunoreactivity within the Kav 0.15 
peak, and a substantial amount of free GLP-1. It 
is possible that the GLP-2 immunoreactive peak at 
Kay 0.23 corresponds to GLP-2 linked to the spacer 
peptide at its N-terminus. 
In the human intestine there is no peak with pro- 
portional GLP-1 and GLP-2 immunoreactivities, 
but there is a peak corresponding to free GLP-1 on 
both gel filtration and HPLC. There is also some 
separate GLP-2 immunoreactivity of greater 
molecular size than synthetic GLP-2; the deficit of 
this with respect to both GLI and GLP-1 im- 
munoreactivity implies, as above, degradation or 
further post-translational modification within the 
GLP-2 sequence, or impaired cross-reactivity of 
possible N-terminally extended forms of GLP-2. 
The lesser deficit of GLP-1 may be similarly 
‘explained. 
The occurrence of free GLP-I in the intestine, 
combined with the demonstration that synthetic 
des-Gly37-GLP-l amide has a glucose-dependent 
insulinotropic effect on isolated rat islets [lo], 
makes GLP-1 a candidate ‘incretin’, i.e. a can- 
didate hormone increasing the insulin response to 
oral nutrient. 
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